A European, multicentre, retrospective, non‐interventional study (EU‐TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes

Publisher： John Wiley & Sons Inc

E-ISSN： 1463-1326|20|3|689-697

ISSN： 1462-8902

Source： DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol.20, Iss.3, 2018-03, pp. : 689-697

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Insulin degludec in Type 1 diabetes

By Eligar Vinay S   Bain Stephen C  

Clinical Investigation, Vol. 3, Iss. 10, 2013-10 ,pp. : 943-950

Future Science

Access to resources Recommend Favorite

Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal–bolus regimens: insights from the PREDICTIVE study

By Hermansen Kjeld   Dornhorst Anne   Sreenan Seamus  

Current Medical Research and Opinion, Vol. 25, Iss. 11, 2009-11 ,pp. : 2601-2608

Informa Healthcare

Access to resources Recommend Favorite

Insulin degludec improves long‐term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal‐bolus insulin therapy

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 2, 2015-02 ,pp. : 202-206

John Wiley & Sons Inc

Access to resources Recommend Favorite

Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes

By  

PEDIATRIC DIABETES (ELECTRONIC), Vol. 16, Iss. 3, 2015-05 ,pp. : 164-176

John Wiley & Sons Inc

Access to resources Recommend Favorite

Insulin degludec/insulin aspart produces a dose‐proportional glucose‐lowering effect in subjects with type 1 diabetes mellitus

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 659-664

John Wiley & Sons Inc

Access to resources Recommend Favorite